About Eisai
Eisai is a company based in Tokyo (Japan) founded in 1941.. The company has 10,920 employees as of March 31, 2024. Eisai has completed 3 acquisitions, including AkaRx, MGI Pharma and Morphotek. Eisai operates in a competitive market with competitors including Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
- Headquarter Tokyo, Japan
- Employees 10920 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eisai Co., Ltd.
-
Annual Revenue
$5.28 B (USD)6.42as on Mar 31, 2025
-
Net Profit
$310.71 M (USD)9.49as on Mar 31, 2025
-
EBITDA
$596.59 M (USD)3.48as on Mar 31, 2025
-
Latest Funding Round
$947.65 K (USD), Grant
Mar 01, 2011
- Investors
-
Employee Count
10920
as on Mar 31, 2024
-
Investments & Acquisitions
AkaRx
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Eisai
Eisai is a publicly listed company on the TSE with ticker symbol 4523 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Leadership Team
88 people
Software Development Team
34 people
Senior Team
29 people
Operations Team
29 people
Finance and Accounting
25 people
Human Resources and Administration
21 people
Data Analysis and Operations Team
21 people
Product Management Team
12 people
Unlock access to complete
Funding Insights of Eisai
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $947,650
-
First Round
First Round
(15 Aug 2007)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2011 | Amount | Grant - Eisai | Valuation |
investors |
|
| Aug, 2007 | Amount | Grant - Eisai | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Eisai
Eisai has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eisai
Eisai has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include AkaRx, MGI Pharma and Morphotek. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Limited information available
|
2005 | ||||
|
Monoclonal antibodies against cancer, inflammatory and infectious diseases.
|
2000 | ||||
|
Oncology and acute care pharmaceuticals are developed and commercialized.
|
1979 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Eisai
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eisai Comparisons
Competitors of Eisai
Eisai operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| domain | founded_year | HQ Location |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| domain | founded_year | HQ Location |
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
|
| domain | founded_year | HQ Location |
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eisai
Frequently Asked Questions about Eisai
When was Eisai founded?
Eisai was founded in 1941 and raised its 1st funding round 66 years after it was founded.
Where is Eisai located?
Eisai is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Who is the current CEO of Eisai?
Haruo Naito is the current CEO of Eisai.
How many employees does Eisai have?
As of Mar 31, 2024, the latest employee count at Eisai is 10,920.
What is the annual revenue of Eisai?
Annual revenue of Eisai is $5.28B as on Mar 31, 2025.
What does Eisai do?
Eisai was founded in 1941 in Tokyo, Japan, and operates in the pharmaceutical sector. Focus is placed on developing treatments for oncology and neurological conditions. Key products include rabeprazole for gastroesophageal reflux disease, risedronic acid for osteoporosis, palonosetron for chemotherapy-induced nausea, donepezil for Alzheimers disease, rufinamide for seizures in Lennox-Gastaut syndrome, lorcaserin for obesity, and dalteparin for deep vein thrombosis and pulmonary embolism. Global operations support drug development and distribution.
Who are the top competitors of Eisai?
Eisai's top competitors include Merck, Roivant Sciences and Amgen.
Is Eisai publicly traded?
Yes, Eisai is publicly traded on TSE under the ticker symbol 4523.
How many acquisitions has Eisai made?
Eisai has made 3 acquisitions, including AkaRx, MGI Pharma, and Morphotek.
Who are Eisai's investors?
Eisai has 1 investor. Key investors include HHS.
What is Eisai's ticker symbol?
The ticker symbol of Eisai is 4523 on TSE.